



## JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis: Effectiveness and Value

Friday • July 23, 2021 • 9am – 3pm ET

Virtual Event – Zoom Webinar

Link to Register: [https://us02web.zoom.us/webinar/register/WN\\_v-BimSsKR\\_-PMPEUwI6iVw](https://us02web.zoom.us/webinar/register/WN_v-BimSsKR_-PMPEUwI6iVw)

Time (ET)	Activity
9:00am – 9:20am	<b>Meeting Convened and Opening Remarks</b> Steven D. Pearson, MD, MSc, President, ICER
9:20am – 9:50am	<b>Presentation of the Clinical Evidence</b> Steven J. Atlas, MD, MPH, Associate Professor of Medicine, Harvard Medical School, Director of Practice Based Research & Quality Improvement, Division of General Internal Medicine, Massachusetts General Hospital
9:50am – 10:20am	<b>Presentation of the Economic Model</b> Elizabeth Brouwer, PhD, MPH, Research Scientist, The CHOICE Institute, Department of Pharmacy, University of Washington
10:20am – 10:50am	<b>Manufacturer Comments and Discussion</b>
10:50am – 11:10am	<b>Public Comments and Discussion</b>
11:10am – 11:25am	<b>Break</b>
11:25am – 12:55pm	<b>New England CEPAC Vote on Clinical Effectiveness and Value</b>
12:55pm – 1:40pm	<b>Lunch Break</b>
1:40pm – 2:50pm	<b>Policy Roundtable</b>
2:50pm – 3:20pm	<b>Reflections from New England CEPAC</b>
3:20pm	<b>Meeting Adjourned</b>

ICER Staff and Consultants	
<b>Foluso Agboola</b> , MBBS, MPH, Vice President of Research, ICER*	<b>Serina Herron-Smith</b> , BA, Senior Research Assistant, Evidence Synthesis, ICER*
<b>Steven J. Atlas</b> , MD, MPH, Associate Professor of Medicine, Harvard Medical School, Director, Practice Based Research & Quality Improvement, Division of General Internal Medicine, MGH*	<b>Maggie Houle</b> , BS, Program and Event Coordinator, ICER*
<b>Elizabeth Brouwer</b> , PhD, MPH, Research Scientist, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington*	<b>Emily Nhan</b> , BA, Research Assistant, ICER*
<b>Jon D. Campbell</b> , PhD, MS, Senior Vice President for Health Economics, ICER*	<b>Steven D. Pearson</b> , MD, MSc, President, ICER*
<b>Josh J. Carlson</b> , PhD, MPH, Associate Professor, The CHOICE Institute, Department of Pharmacy, University of Washington*	<b>David M. Rind</b> , MD, MSc, Chief Medical Officer, ICER*
<b>Yilin Chen</b> , MPH, PhD Student, The CHOICE Institute, Department of Pharmacy, University of Washington*	<b>Liis Shea</b> , MA, Program Director, ICER*
<b>Ryan N. Hansen</b> , PharmD, PhD, Associate Professor, The CHOICE Institute, Department of Pharmacy, University of Washington*	

\*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Participating Members of CEPAC	
<b>Robert Aseltine</b> , PhD, Professor and Chair, Division of Behavioral Sciences and Community Health, UCONN Health*	<b>Greg Low</b> , RPh, PhD, Director, MGPA Pharmacy Quality and Utilization Program, Massachusetts General Hospital*
<b>Kelly Buckland</b> , MS, Executive Director, National Council on Independent Living*	<b>Eleftherios Mylonakis</b> , MD, PhD, FIDSA, Professor of Infectious Disease, Chief of Infectious Disease, Brown University*
<b>Christopher Jones</b> , PhD, MSc, Director, Ventures Investments, UVM Health Network*	<b>Leslie Ochs</b> , PharmD, PhD, MSPH, Associate Professor and Department Chair, University of New England School of Pharmacy*
<b>Rebecca Kirch</b> , JD, Executive Vice President of Policy and programs, National Patient Advocate Foundation*	<b>Jeanne Ryer</b> , MSc, EdD, Director, NH Citizens Health Initiative*
<b>Stephen Kogut</b> , PhD, MBA, RPh, Professor, University of Rhode Island College of Pharmacy*	<b>Jason L. Schwartz</b> , PhD, Associate Professor of Health Policy, Yale School of Public Health*
<b>Donald M. Kreis</b> , MS, JD, Consumer Advocate, New Hampshire Office of the Consumer Advocate*	<b>Jason Wasfy</b> , MD, MPhil, Medical Director, Mass General Physicians Organization*
<b>Tara Lavelle</b> , PhD, Assistant Professor, Tufts Medical Center*	<b>Albert Whitaker</b> , MA, MPH, Director of Community Impact, American Heart Association*
<b>Kimberly Lenz</b> , PharmD, FAMCP, Director of Clinical and Operational Pharmacy, University of Massachusetts Medical School*	

\*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Policy Roundtable Participant	Conflict of Interest
<b>Samantha Bittner</b> , Patient Ambassador, National Eczema Association	No financial conflicts to disclose.
<b>Thomas Brownlie</b> , MS, Senior Director, Pfizer Inc.	Thomas is a full-time employee of Pfizer Inc.
<b>Jeffrey Casberg</b> , MS, RPh, Vice President of Pharmacy, IPD Analytics	Jeffrey is a full-time employee of IPD Analytics.
<b>Michele Guadalupe</b> , MPH, Associate Director of Advocacy and Access, National Eczema Association	The National Eczema Association has received grants and sponsorship awards from a variety of industry partners, including Pfizer, AbbVie, Sanofi, Regeneron, Incyte, and LEO Pharma.
<b>Catherine Herren</b> , PharmD, MS, Advisor, Value Development, Eli Lilly, and Company	Dr. Catherine Herren is a full-time employee of Eli Lilly and Company.
<b>Kyle Hvidsten</b> , MPH, Vice President, Head of Global Health Economics and Value Assessment, Sanofi	Kyle is a full-time employee of Sanofi.
<b>Erik Schindler</b> , PharmD, Director, Emerging Therapeutics and Outcome-Based Contracting, UnitedHealthcare Pharmacy	Dr. Erik Schindler is a full-time employee of UnitedHealthcare Pharmacy.
<b>Elaine Siegfried</b> , MD, Professor of Pediatrics and Dermatology, Saint Louis University School of Medicine	Dr. Elaine Siegfried has received consulting fees and honoraria from industry partners, including Incyte, Regeneron, Sanofi, LEO Pharma, Pfizer, and AbbVie for participation in clinical trials as a PI. She also received funding from Pfizer to support a two-year fellowship position at Saint Louis University.
<b>Jonathan Silverberg</b> , MD, PhD, MPH, Associate Professor, George Washington University School of Medicine and Health Sciences	Dr. Jonathan Silverberg has received funding from industry partners, including AbbVie, Eli Lilly, Incyte, LEO Pharma, Regeneron, and Sanofi.
<b>Andrine Swensen</b> , PhD, MS, Senior Director HEOR, Market Access and Public Affairs, Leo Pharma	Dr. Swensen is a full-time employee of Leo Pharma.